In addition to drug-screening capabilities, the value of molecular-sensitive SC-QDP measurements was illustrated in clinical samples by identification of CD34+ cells that are phosphoinsensitive to the kinase inhibitor, dasatinib, the standard KI for many leukemia patients with CML. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.